Fiche publication


Date publication

septembre 2022

Journal

ESC heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick


Tous les auteurs :
Monzo L, Ferreira JP, Cleland JGF, Pellicori P, Mariottoni B, Hazebroek MR, Collier TJ, Cuthbert JJ, Pieske B, Petutschnigg J, Ahmed FZ, Girerd N, Clark AL, Cosmi F, Staessen JA, Heymans S, Rossignol P, Zannad F

Résumé

In people at risk of heart failure (HF) enrolled in the Heart 'OMics' in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen synthesis, natriuretic peptides, and blood pressure and improved cardiac structure and function. In the present report, we explored factors associated with dyskalaemia.

Mots clés

Heart failure prevention, Hyperkalaemia, Hypokalaemia, Steroidal mineralocorticoid receptor antagonist

Référence

ESC Heart Fail. 2022 09 6;: